Neoplasms, Nerve Tissue Clinical Trials

16 clinical trials for Neoplasms, Nerve Tissue across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors — RECRUITING · PHASE1
• Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) — RECRUITING · PHASE1
• A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients — RECRUITING · PHASE3
• Spanish Series of Patients Treated With the Radionuclide Lutetium177 — RECRUITING
• Vorasidenib Expanded Access Program — OTHER
• Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients — COMPLETED · NA
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) — TERMINATED · PHASE3
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors — COMPLETED · PHASE1
• (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC — TERMINATED · PHASE1
• (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC — TERMINATED · PHASE1
• External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC — OTHER
• Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. — OTHER · PHASE1
• Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients — COMPLETED · NA
• Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) — WITHDRAWN · PHASE2
• A Combined Cell Therapy Approach to the Treatment of Neuroblastoma — WITHDRAWN · PHASE1
• Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients — OTHER

Refine this search